Valentin Baloche
University of Paris-Sud
8 Papers
5 Citations
Valentin Baloche is an academic researcher from University of Paris-Sud. The author has contributed to research in topics: Nasopharyngeal carcinoma & Medicine. The author has an hindex of 3, co-authored 4 publications. Previous affiliations of Valentin Baloche include Institut Gustave Roussy.
Chat about Author
Papers
Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
Anna Makowska,Till Braunschweig,Bernd Denecke,Lian Shen,Valentin Baloche,Philippe Busson,Udo Kontny +6 more
TL;DR: Combination of IFNβ and anti-PD-1, augmenting cytotoxicity of NK cells against NPC cells, could be a strategy to improve NPC-directed therapy and warrants further evaluation in vivo.
31
Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges
Valentin Baloche,François-Régis Ferrand,Anna Makowska,Caroline Even,Udo Kontny,Philippe Busson +5 more
TL;DR: This article examines targets related to cellular oncogenic alterations, latent EBV infection and tumor interactions with the immune system, especially those related to NK cells, as well as new agents that target EBV products.
16
Tumor exosomal microRNAs thwarting anti-tumor immune responses in nasopharyngeal carcinomas.
TL;DR: The considerable progress achieved in the past 10 years in the field of tumor biology and therapeutics has strengthened the idea that cancer is not only a cellular but also a tissue disease, and this concept is likely to apply to nasopharyngeal carcinoma, characterized by the consistent expression of oncogenic viral proteins in a context of inflammation and immune escape.
6
Op0215 immunome analysis indicates robust inhibition of proinflammatory mediators upon leflunomide-hydroxychloroquine combination therapy in sjögren’s syndrome: cxcr3 ligands as potential inflammatory endotype biomarkers.
Valentin Baloche,C. H. M. Bogers,Helen L. Leavis,J A G van Roon +3 more
TL;DR: Mavragani et al. as discussed by the authors employed a high-throughput protein Olink proteomic assay (Immuno-Oncology panel) to determine the blood serum concentrations of 92 immune biomarkers, assessed at baseline and at the clinical endpoint in placebo (n=8) and verum treated patients (n =21).